Polycystic ovary syndrome affects 20% of women of reproductive age. The increasing awareness of the metabolic abnormalities associated with the syndrome has lead to concern about the cardiovascular risk and its long-term health implications. Women with polycystic ovary syndrome are characterised by insulin resistance, central obesity and dyslipidemia which places them at a higher risk of developing diabetes and cardiovascular disease. Assessment of lipid profile and glucose tolerance should be considered. Since these women are at increased risk of endometrial carcinoma, assessment should be offered. The standard criteria for the prescription of hormone replacement therapy apply.
. BalenAHConwayGSKaltasGTechatraisakKManningPWestCJacobsHS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod1995; 10: 2107–2111.
2.
. ClaytonRNOgdenVHodgkinsonVWorswickLRodinDADyerSMeadeDW. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?Clin Endocrinol1992; 37: 127–134.
3.
. PolsonDWAdamsJWadsworthJFranksS.Polycystic ovaries - a common finding in normal women. Lancet1988; I: 870–872.
4.
. AndersonKESellersTAChenPLRichSSHongCPFolsomAR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer1997; 79: 494–9.
. HopkinsonZECSattarNFlemingRGreerIA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ1998; 317: 329–332.
7.
. McKeigueP.Cardiovascular disease and diabetes in women with polycystic ovary syndrome. Balliere's Clin Endocrinol Metab1996; 10: 311–318.
8.
. EakerEChesebroJHSacksFMWengerNKWhisnantJPWinstonM. Cardiovascular disease in women. Circulation1993; 88: 1999–2009.
9.
. BurghenGAGivensJRKitabchiAE. Correlation of hyoerandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab1980; 50: 113–116.
10.
. ChangRJNakamuraRMJuddHIKaplanSA. Insulin resistance in nonobese patients with polycystic ovary syndrome. J Clin Endocrinol Metab1983; 57: 356–359.
11.
. DunaifASegalKRFutterweitWDobrjanskyA.Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes1989; 38: 1165–1174.
12.
. ConwayGSJacobsHSHollyJMWassJA. Effects of luteinizing hormone, insulin, insulin like growth factor and insulin like growth factor small binding protein in polycystic ovary syndrome. Clin Endocrinol1990; 33: 593–603.
13.
. JialalINaikerPReddiKMoodleyJJoubertSM. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab1987; 64: 1066–1069.
14.
. OvesenPMollerJIngerslevHJ. Normal basal and insulin stimulated fuel metabolism in lean women with polycystic ovary syndrome. J Clin Endocrinol Metab1993; 77: 1636–40.
15.
. HolteJBerghTBerneCBerglundLLithellH.Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab1994; 78: 1052–1058.
16.
. RajkhowaMBicknellJJonesMClaytonRN. Insulin sensitivity in obese and nonobese women with polycystic ovary syndrome-relationship to hyperandrogenaemia. Fertil Steril1994; 61: 605–11.
17.
. DalePOTombTVaolirSAbyholmT.Body weight, hyperinsulinaemia and gonadotrophin levels in the polycystic ovary syndrome: evidence of two distinct populations. Fertil Steril1992; 58: 487–491.
18.
. AntillaIDingYqRuuitiaianenKErkkolaRIrjalalKHuhtaniemiI.Clinical features and circulating gonadotrophin, androgen, and insulin interactions in women with features of polycysatic ovary syndrome. Fertil Steril1991; 55: 1057–1061.
19.
. RobinsonSKiddyDGeldingSVWillisDNithyanathanRBushAJohnstonDGFranksS.The relation of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol1993; 39: 351–355.
20.
. ConwayGSHonourJWJacobsHS. Heterogeneity of the polycystic ovary syndrome - clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol1989; 30: 459–470.
21.
. FalconeTFinegoodDtFantusGMorrisD.Androgenous response to endogenous insulin secretion during frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab1990; 71: 1653–1657.
. EvansDJHoffmanDGKalkhoffRKKissebahAH. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab1983; 57: 304–310.
24.
. Rebuffe-ScriveMCulbergGLundbergPA. Anthropometric variables and metabolism in polycystic ovarian disease. Hormone & Metabolic Research1989; 21: 391–397.
25.
. TalbottEGuzickDClericiABergaSDetreKWeimerKKullerL.Coronary heart disease risk factors in women with polycystic ovary syndrome. Arteriosclerosis, Thrombosis and Vascular Biology1995; 15: 821–826.
26.
. DahlgrenEJohanssonSLindstedtG. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril1992; 57: 505–13.
27.
. DunaifA.Insulin resistance in polycystic ovary syndrome. Ann NY Acad Sci, eds. TolisGBringerJChrousosGP. 1993; 687-; 60–64.
28.
. GjonnaessH.The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body weight. Br J Obstet Gynaecol1989; 96: 714–719.
29.
. WildRAPainterPCCoulsonPB. Lipoprotein lipid concentrations and cardiovasular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab1985; 61: 946–51.
30.
. ConwayGSAgrawalRBetterridgeDJ. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol1992; 37: 119–25.
31.
. GrafMRichardsCJBrownV. The independent effects of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol1990; 33: 119–31.
32.
. HolteJBerghTBerneCLithellH.Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol1994; 41: 463–71.
33.
. BlassKMNewschafferCJKlagMJBushTL. Plasma lipoprotein levels as predictor of cardiovascular death in women. Arch Intern Med1993; 153: 2209–2216.
34.
. RajkhowaMNearyRHKnmptalaPGameFLJonesPObhraiMSClaytonRN. Altered composition of high density lipoproteins in women with polycystic ovary syndrome. J Clin Endocrinol Metab1997; 82: 3389–3394.
35.
. AtiomoWUBatesSACondonJEShawSWestJHPrenticeAG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril1998; 69: 236–241.
36.
. SampsonMKongCPatelAUnwinRJacobsHS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without polycystic ovary syndrome. Clini Endocrinol1996; 45: 623–629.
37.
. DahlgrenEJansonPOJohanssonSLapidusLOdenA.Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynaecol Scand1992; 71: 599–604.
38.
. AchardCThiersJ.Le virilisme pilaire et son associationa avec l'insuffisance glycolytique (diabetes a femmes de barbes)Bull Acad Natl Med (Paris)1921; 86: 51–66.
39.
. PierpointTMcKeiguePMIssacsAJWildSJJacobsHS. Mortality in women with polycystic ovary syndrome at long term follow up. J Clin Epidemiol.1998; 51: 581–586.
40.
. WildRAAplebaum-BowdenDDemersLM. Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen. Clinical Chemistry1990; 36: 283–89.
41.
. BirdsallMAFarquharCMWhiteHD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterisation. Ann Intern Med1997; 126: 32–35.
